stockrowAMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
Follow AMRX
Alert me
AMNEAL PHARMACEUTICALS, INC. (AMRX) EBITDA
AMNEAL PHARMACEUTICALS, INC.'s EBITDA for fiscal 2025 was $640.1M, up 24.4% from $514.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $664.9M. Over the past ten years it has ranged from $1.4M (fiscal 2019) to $640.1M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 3 consecutive fiscal years. AMNEAL PHARMACEUTICALS, INC. ranks 9th of 80 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $640.1M | 24.38% |
| FY2024 | $514.6M | 15.56% |
| FY2023 | $445.3M | 189.47% |
| FY2022 | $153.8M | (61.08%) |
| FY2021 | $395.3M | 17.93% |
| FY2020 | $335.2M | 23,439.07% |
| FY2019 | $1.4M | (98.94%) |
| FY2018 | $134.0M | (54.67%) |
| FY2017 | $295.6M | (7.89%) |
| FY2016 | $321.0M | 132.23% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $181.6M | (3.82%) |
| Mar 2026 | $188.9M | 14.47% |
| Dec 2025 | $165.0M | 27.45% |
| Sep 2025 | $129.4M | (27.42%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| AMRX AMNEAL PHARMACEUTICALS, INC. | $664.9M |
| SUPN Indivior Pharmaceuticals Inc. compare | $571.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $526.8M |
| LNTH Lantheus Holdings, Inc. compare | $386.4M |
| ALKS Alkermes plc compare | $217.3M |
| LQDA Liquidia Corporation compare | $170.3M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $132.4M |
| HIMS Hims & Hers Health, Inc. compare | −$62.2M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on AMRX
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement